Treatments that antagonize VEGF attenuate the gradual increase in dyskinesia severity during a chronic course of l-DOPA administration (43, 141), while inhibiting the angiogenic activity and BBB dysfunction induced by l-DOPA in the basal ganglia (43). The gene discussed is VEGFA; the disease is drug-induced dyskinesia.